Advanced Instruments the launch of Solentim VIPS PRO, a high efficiency single cell seeder, at the BioProcess International Conference in Boston, Massachusetts.
VIPS PRO revolutionizes cell line development (CLD) and GMP manufacturing by combining powerful seeding technology with two-step, image-based proof of monoclonality and proprietary Artificial Intelligence-driven cell recognition for increased productivity and confidence.
A major challenge in CLD is providing absolute proof of clonal line generation that regulatory authorities require. VIPS PRO offers a unique Double-Lock Assurance of clonality, generating the two pieces of image-based evidence required for IND submission.
Compared to other methods, such as limiting dilution, VIPS PRO's industry-leading seeding and clonal assurance process eliminates human error, reduces hands-on time, and accelerates process development and clinical manufacturing.
Based on the original VIPS technology, VIPS PRO is an indispensable technology for bringing innovative biotherapeutics to market. The instrument delivers a of range benefits for GMP-compatible clinical manufacturing labs, including:
Highly efficient, automated single cell seeding
Two-step, image-based Double-Lock Assurance of clonality
Intelligent cell detection
Single-use, GMP-friendly consumables
Advanced data management and analysis with the STUDIUS™ software platform
GMP-compatible workflow, including security features that support 21 CFR Part 11 compliance
Ergonomic instrument design with easy-to-access components
"VIPS PRO is a game-changer for single cell seeding, combining powerful, efficient seeding technology with definitive image-based proof—NOT probability—of monoclonality," said Byron Selman, CEO of Advanced Instruments.
"At Advanced Instruments, customer feedback is integral to what we do and how we design new products. VIPS PRO builds on our trusted VIPS technology with thoughtful updates that meet the needs of our customers."
VIPS PRO is part of an ecosystem of technologies from Advanced Instruments built to accelerate cell line development workflows, from initial discovery to scale-up and manufacturing of biotherapeutics.
For more information, please visit www.aicompanies.com